FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion

BACKGROUND: Immune compromised mice are increasingly used for the preclinical development of monoclonal antibodies (mAb). Most common are non-obese diabetic (NOD) severe combined immunodeficient (SCID) and their derivatives such as NOD SCID interleukin-2 γ-/- (NSG), which are attractive hosts for pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Oldham, Robert J, Mockridge, C Ian, James, Sonya, Duriez, Patrick J, Chan, H T Claude, Cox, Kerry L, Pitic, Vicentiu A, Glennie, Martin J, Cragg, Mark S
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Basic Tumor Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7304853/
https://ncbi.nlm.nih.gov/pubmed/32554613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000619
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados